

programs, and other services to its members.

The proposed action encompasses the various Federal approvals which may be required to implement the Tribe's proposed economic development project, including approval of the Nation's fee-to-trust application. The EIS will identify and evaluate issues related to these approvals, and will also evaluate a range of reasonable alternatives, including a no action alternative. Other possible alternatives currently under consideration are a reduced-intensity gaming facility alternative, an alternate-use (non-gaming) alternative and an off-site alternative. The range of issues and alternatives may be revised based on comments received during the scoping process.

Areas of environmental concern preliminarily identified for analysis in the EIS include land resources; water resources; air quality; noise; biological resources; cultural/historical/archaeological resources; resource use patterns; traffic and transportation; public health and safety; hazardous materials and hazardous wastes; public services and utilities; socioeconomic; environmental justice; visual resources/aesthetics; and cumulative, indirect, and growth-inducing effects. Additional information, including a map of the project site, is available by contacting the person listed in the **FOR FURTHER INFORMATION** section of this notice.

**Public Comment Availability:** Comments, including names and addresses of respondents, will be available for public review at the BIA address shown in the **ADDRESSES** section, during regular business hours, 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. Before including your address, telephone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask in your comment that your personal identifying information be withheld from public review, the BIA cannot guarantee that this will occur.

**Authority:** This notice is published in accordance with sections 1503.1 and 1506.6 of the Council on Environmental Quality Regulations (40 CFR parts 1500 through 1508) implementing the procedural requirements of the National Environmental Policy Act of 1969, as amended (42 U.S.C. 4321–4345 *et seq.*), and the Department of the Interior National Environmental Policy Act Regulations (43 CFR part 46), and is in the exercise of authority delegated to the

Assistant Secretary—Indian Affairs by 209 DM 8.

Dated: December 21, 2015.

**Kevin K. Washburn,**

*Assistant Secretary—Indian Affairs.*

[FR Doc. 2015–33247 Filed 1–5–16; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF THE INTERIOR

### Bureau of Land Management

[LLMTB07900 15XL1109AF L10100000  
PH0000 LXSIANMS0000 MO# 4500089261]

### Notice of Public Meeting; Western Montana Resource Advisory Council

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Notice of Public Meeting.

**SUMMARY:** In accordance with the Federal Land Policy and Management Act (FLPMA) and the Federal Advisory Committee Act of 1972 (FACA), the U.S. Department of the Interior, Bureau of Land Management (BLM) Western Montana Resource Advisory Council (RAC) will meet as indicated below.

**DATES:** The Western Montana Resource Advisory Council meeting will be held January 27, 2016 in Butte, Montana. The meeting will begin at 9:00 a.m. in the Butte Field Office conference room, with a 30-minute public comment period starting at 11:30 a.m., and will adjourn at 3:00 p.m.

**ADDRESSES:** BLM's Butte Field Office, 106 N. Parkmont, Butte, MT.

#### FOR FURTHER INFORMATION CONTACT:

David Abrams, Western Montana Resource Advisory Council Coordinator, Butte Field Office, 106 North Parkmont, Butte, MT 59701, 406–533–7617, [dabrams@blm.gov](mailto:dabrams@blm.gov). Persons who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339 to contact the above individual during normal business hours. The FIRS is available 24 hours a day, 7 days a week, to leave a message or question with the above individual. You will receive a reply during normal business hours.

**SUPPLEMENTARY INFORMATION:** This 15-member council advises the Secretary of the Interior through the BLM on a variety of management issues associated with public land management in Montana. During this meeting the council will discuss several topics, including a briefing on weed treatments in the BLM's Western Montana District, and updates from the BLM's Butte, Missoula and Dillon field offices. All RAC meetings are open to the public. The public may present written

comments to the RAC. Each formal RAC meeting will also have time allocated for hearing public comments. Depending on the number of persons wishing to comment and time available, the time for individual oral comments may be limited.

**Authority:** 43 CFR 1784.4–2.

**Richard M. Hotaling,**

*District Manager, Western Montana District.*

[FR Doc. 2015–33270 Filed 1–5–16; 8:45 am]

**BILLING CODE 4310-DN-P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on Mechanical Stratigraphy and Natural Deformation in Eagle Ford Formation and Equivalent Boquillas Formation, South-Central and West Texas (Eagle Ford II)

Notice is hereby given that, on December 7, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Cooperative Research Group on Mechanical Stratigraphy and Natural Deformation in Eagle Ford Formation and Equivalent Boquillas Formation, South-Central and West Texas (“Eagle Ford II”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, BHP Billiton Petroleum (Americas) Inc., has changed its name to BHP Billiton Petroleum (Deepwater) Inc., Houston, TX.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Eagle Ford II intends to file additional written notifications disclosing all changes in membership.

On July 1, 2015, Eagle Ford II filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal**

**Register** pursuant to section 6(b) of the Act on July 29, 2015 (90 FR 45234).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2015–33267 Filed 1–5–16; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Chemical & Biological Defense Consortium

Notice is hereby given that, on November 13, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), National Chemical & Biological Defense Consortium (“NCBDC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: AbViro LLC, Bethesda, MD; Advanced Nuclear Devices Corporation, Hilton Head Island, SC; Aequor, Inc., Oceanside, CA; Aeterna Zentaris, Québec, CANADA; AIBiotech, Richmond, VA; Allied Technologies & Consulting, LLC, Frederick, MD; AMH Consulting, Potomac, MD; AntibioTx ApS, Hørsholm, DENMARK; Approach Robotics, Ridgecrest, CA; Aradigm Corporation, Hayward, CA; Artificial Cell Technologies, Inc., New Haven, CT; BalinBac Therapeutics, Inc., Princeton, NJ; Battelle Memorial Institute, Columbus, OH; BioFactura, Inc., Frederick, MD; BioStat Solutions, Inc., Frederick, MD; Burrell International Group, LLC, Frederick, MD; CACI, Arlington, VA; CFD Research Corporation, Huntsville, AL; CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Creare LLC, Hanover, NH; CSC Government Solutions LLC, Falls Church, VA; CUBRC, Inc., Buffalo, NY; DALI Medical Devices Ltd., Yavne, ISRAEL; Design West Technologies Inc., Tustin, CA; Draper Laboratory, Cambridge, MA; Eagle Applied Science, San Antonio, TX; Emergent, Inc., North Charleston, SC; Equivital Inc., New York, NY; EZ–A Consulting, LLC, Bel

Air, MD; First Line Technology, Chantilly, VA; General Dynamics Information Technology, San Diego, CA; GeoVax Labs, Inc., Smyrna, GA; Ginkgo BioWorks, Boston, MA; Goldbelt Raven, LLC, Herndon, VA; Hackensack University Medical Center, Hackensack, NJ; iBio, Inc., New York, NY; IIT Research Institute, Chicago, IL; Immune Biosolutions, Inc., Québec, CANADA; Inficon, East Syracuse, NY; Integrated BioTherapeutics, Inc., Gaithersburg, MD; InvivoSciences Inc., Madison, WI; Jade Therapeutics, Inc., Salt Lake City, UT; JRAD, Stafford, VA; KD Analytical, Harrisburg, PA; Kestrel Corporation, Albuquerque, NM; Kinnear Pharmaceuticals, LLC, Columbus, OH; Kiyatec, Greenville, SC; L–3 Communications, New York, NY; Latham BioPharm Group, Inc., Maynard, MA; Luminex Corporation, Austin, TX; MainStream Global Solutions, Robins, IA; Mapp Biopharmaceutical, Inc., San Diego, CA; MaxCyte, Inc., Gaithersburg, MD; Med-Ally, Canton, CT; MedPro Technologies, LLC, San Antonio, TX; Mesa Science Associates Inc., Frederick, MD; Michael T. Brown Consulting, LLC, Austin, TX; Microbial Robotics, LLC, Covington, KY; Mike Sellers & Associates, Beavercreek, OH; MLT Systems, Stafford, VA; MRI Global, Kansas City, MO; Nanotherapeutics, Inc., Alachua, FL; New York Blood Center Inc., New York, NY; Novici Biotech LLC, Vacaville, CA; Novozymes, Inc., Franklinton, NC; OrPro Therapeutics, Inc., San Diego, CA; Parsons, Washington, DC; Pertexa, Ridgecrest, CA; Philips, Foster City, CA; PrEP Biopharm, Rumson, NJ; Purdue University, West Lafayette, IN; QuickSilver Analytics, Belcamp, MD; Quintiles, Durham, NC; Rapid Pathogen Screening, Inc. (RPS), Sarasota, FL; Recursion Pharmaceuticals, Salt Lake City, UT; RTI International, Coraopolis, PA; San Diego State University, San Diego, CA; Science Applications International Corporation, McLean, VA; SciTech Services Inc., Havre De Grace, MD; Shield Analysis Technology, LLC, Manassas, VA; SIGA Technologies, Inc., New York, NY; Signature Science, Austin, TX; Smart Consulting Group, LLC, West Chester, PA; Southern Research Institute, Birmingham, AL; Southwest Research Institute, San Antonio, TX; Spero Therapeutics, Cambridge, MA; SRI International, Princeton, NJ; Strategic Solutions Integrated, Arlington, VA; TDA Research, Inc., Wheat Ridge, CO; Tetracore, Inc., Rockville, MD; Texas A&M, Bryan, TX; TheraSource LLC, Roslyn, NY; Trideum, Huntsville, AL; TriLink BioTechnologies, San Diego,

CA; Ubiquitome Limited, Auckland, NEW ZEALAND; University of Florida Institute for Therapeutic Innovation, Gainesville, FL; University of Nebraska Medical Center—Department of Pathology and Microbiology, Omaha, NE; University of North Texas Health Sciences Center, Fort Worth, TX; University of Pittsburgh—Center for Military Medicine Research, Pittsburgh, PA; and Vaxess Technologies, Inc., Cambridge, MA. The general area of NCBDC’s planned activity is advanced development efforts to support the Department of Defense’s medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel through (i) detection—systems and devices to identify CBRN (Chemical Biological Radiological and Nuclear) agents and assist in making medical decisions; (ii) prevention—prophylaxis, pretreatment, and post-exposure prophylaxis; (iii) treatment—therapeutics (post-exposure, post-symptomatic); and (iv) chemical—medical protection against use of chemical agents.

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2015–33266 Filed 1–5–16; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—ASTM International Standards

Notice is hereby given that, on December 11, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), ASTM International (“ASTM”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, ASTM has provided an updated list of current, ongoing ASTM standards activities originating between September 2015 and December 2015 designated as Work Items. A complete listing of ASTM Work Items along with a brief description of each, is available at <http://www.astm.org>.